Summary
Global Markets Direct’s, ‘Agenus, Inc. - Product Pipeline Review - 2016’, provides an overview of the Agenus, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Agenus, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Agenus, Inc.
- The report provides overview of Agenus, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Agenus, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Agenus, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Agenus, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Agenus, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Agenus, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Agenus, Inc. Snapshot 7
Agenus, Inc. Overview 7
Key Information 7
Key Facts 7
Agenus, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Agenus, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Agenus, Inc. - Pipeline Products Glance 17
Agenus, Inc. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Agenus, Inc. - Early Stage Pipeline Products 19
IND/CTA Filed Products/Combination Treatment Modalities 19
Preclinical Products/Combination Treatment Modalities 20
Agenus, Inc. - Drug Profiles 21
G-100 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
G-200 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
PxM-01 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
AGEN-1884 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
AGEN-2041 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibodies for Cancer 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibodies for Oncology 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibody for Cancer 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody to Inhibit PD-1 for Cancer 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibody to Target CEACAM-1 for Oncology 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Vaccine for Oncology 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Agenus, Inc. - Pipeline Analysis 33
Agenus, Inc. - Pipeline Products by Target 33
Agenus, Inc. - Pipeline Products by Route of Administration 34
Agenus, Inc. - Pipeline Products by Molecule Type 35
Agenus, Inc. - Pipeline Products by Mechanism of Action 36
Agenus, Inc. - Recent Pipeline Updates 37
Agenus, Inc. - Dormant Projects 40
Agenus, Inc. - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
Aroplatin 41
HSPPC-70 41
Agenus, Inc. - Company Statement 42
Agenus, Inc. - Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46
List of Tables
Agenus, Inc., Key Information 7
Agenus, Inc., Key Facts 7
Agenus, Inc. - Pipeline by Indication, 2016 10
Agenus, Inc. - Pipeline by Stage of Development, 2016 11
Agenus, Inc. - Monotherapy Products in Pipeline, 2016 12
Agenus, Inc. - Partnered Products in Pipeline, 2016 13
Agenus, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 14
Agenus, Inc. - Out-Licensed Products in Pipeline, 2016 15
Agenus, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
Agenus, Inc. - Phase II, 2016 17
Agenus, Inc. - Phase I, 2016 18
Agenus, Inc. - IND/CTA Filed, 2016 19
Agenus, Inc. - Preclinical, 2016 20
Agenus, Inc. - Pipeline by Target, 2016 33
Agenus, Inc. - Pipeline by Route of Administration, 2016 34
Agenus, Inc. - Pipeline by Molecule Type, 2016 35
Agenus, Inc. - Pipeline Products by Mechanism of Action, 2016 36
Agenus, Inc. - Recent Pipeline Updates, 2016 37
Agenus, Inc. - Dormant Developmental Projects,2016 40
Agenus, Inc. - Discontinued Pipeline Products, 2016 41
Agenus, Inc., Subsidiaries 44
List of Figures
Agenus, Inc. - Pipeline by Top 10 Indication, 2016 9
Agenus, Inc. - Pipeline by Stage of Development, 2016 11
Agenus, Inc. - Monotherapy Products in Pipeline, 2016 12
Agenus, Inc. - Partnered Products in Pipeline, 2016 13
Agenus, Inc. - Out-Licensed Products in Pipeline, 2016 15
Agenus, Inc. - Pipeline by Top 10 Target, 2016 33
Agenus, Inc. - Pipeline by Top 10 Molecule Type, 2016 35
Agenus, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 36
